Loaiza-Bonilla offers advice on optimizing treatment selection in pancreatic cancer
welcome to OncLive On Air®! I am your host today, Caroline Seymour.
OncLive On Air® is a podcast of OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In digital and printed format, OncLive® covers all aspects of oncology practice, from new technologies and therapeutic advances to important regulatory decisions.
In today’s episode, sponsored by Ipsen, we had the pleasure of speaking with Arturo Loaiza-Bonilla, MD, MSEd, FACP, Cancer Treatment Centers of America, Medical Director of Clinical Research and Program Director gastrointestinal at CTCA Atlanta, to discuss treatment planning in pancreatic cancer metastasis.
In our exclusive interview, Loaiza-Bonilla discussed the first-line treatment selection approaches in metastatic pancreatic cancer, the effects of adverse reactions and toxicities in treatment planning, and the treatment options available to patients afterwards. diets containing gemcitabine.
Check back on Mondays and Thursdays for exclusive interviews with leading experts in the field of oncology. For more information on oncology, be sure to visit www.OncLive.com and sign up for our email newsletters.
OncLive® is also present on social networks. On Twitter, follow us on @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms *, so you receive a notification every time a new episode is published. While you’re at it, please take a moment to rate us!
Thanks again for listening OncLive On Air®.
* OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic and TuneIn.